ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
| Revenue (TTM) | $5.65B |
| Gross Profit (TTM) | $3.48B |
| EBITDA | $2.10B |
| Operating Margin | 30.90% |
| Return on Equity | 24.30% |
| Return on Assets | 14.00% |
| Revenue/Share (TTM) | $38.85 |
| Book Value | $45.66 |
| Price-to-Book | 5.02 |
| Price-to-Sales (TTM) | 5.83 |
| EV/Revenue | 5.73 |
| EV/EBITDA | 15.06 |
| Quarterly Earnings Growth (YoY) | 2.40% |
| Quarterly Revenue Growth (YoY) | 8.60% |
| Shares Outstanding | $144.25M |
| Float | $143.37M |
| % Insiders | 0.50% |
| % Institutions | 71.44% |
Volatility is currently contracting
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026. Resmed's webcast presentation will begin at approximately 10:00 a.m. (Eastern Time).
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed's current Lead Director, who is not standing for reelection at the company's 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.
Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.
Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.
Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RMD and any ticker you trade — then tracks every position and per-strategy win rate.
